← Eichor
Study identifier: NCT05394506 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Modifying Factors in Striated Muscle Laminopathies

Condition: Laminopathies · Emery Dreifuss Muscular Dystrophy 2 · LMNA-Related Congenital Muscular Dystrophy  ·  Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

PhaseNA
Planned participants40
Who can joinAll sexes, 2 Years to no upper limit
Healthy volunteersNo

About this study

Mutations in the LMNA gene, which codes for lamins A and C, proteins of the nuclear lamina, are responsible for a wide spectrum of pathologies, including a group specifically affecting striated skeletal and cardiac muscles, with cardiac involvement being life-threatening. At the skeletal muscle level, a wide phenotypic spectrum has been described, ranging from severe forms of congenital muscular dystrophy to less severe forms of limb-girdle muscular dystrophy. The great clinical variability of striated muscle laminopathies, both inter- and intra-familial, can be observed in the age of onset, severity of signs and progression of muscle and heart involvement. To date, more than 400 LMNA mutations have been associated with striated muscle laminopathies (www.umd.be/LMNA/), highlighting strong clinical and genetic heterogeneity. A few recurrent mutations linked to a difference in severity have been identified. However, these genotype-phenotype relationships and the rare cases of digenism reported do not explain all the clinical variability of laminopathies. Therefore, there are probably other factors of severity than the causative mutation, called "modifier genes". Identification of such modifier genes has been initiated by studying a large family with significant clinical variability in the age of onset of muscle signs. A segregation analysis within this family identified 2 potential modifier loci. High-throughput sequencing restricted to these 2 regions according to phenotypic …

This description comes directly from the study's public registry record.

Talk to the study team

Gisele Bonne, Phd  ·  +33142165724  ·  g.bonne@institut-myologie.org

Rabah Ben Yaou, MD  ·  +33142165735  ·  r.benyaou@institut-myologie.org

Always discuss trial participation with your own doctor first.

Locations (8)

Centre de référence maladies neuromusculaires, Hôpital Femme Mère Enfant, CHU LyonBron, Auvergne-Rhône-Alpes, FranceRecruiting
Centre de référence maladies neuromusculaires, Institut de myologie, Hôpital Pitié-SalpêtrièreParis, France, FranceRecruiting
Service de Neuropédiatrie, Centre de Référence Maladies Neuromusculaires, CHU de MontpellierMontpellier, Hérault, FranceNot Yet Recruiting
Service de Génétique médicale, CHU RennesRennes, Ille-et-Vilaine, FranceNot Yet Recruiting
Laboratoire d'Explorations Fonctionnelles - Centre de Référence Maladies Neuromusculaires Rares, CHU NantesNantes, Loire-Atlantique, FranceNot Yet Recruiting
Service de cardiologie & Service de Neurophysiologie - CHU de RouenRouen, Normandy, FranceRecruiting
Centre de référence pour les maladies cardiaques héréditairesParis, Paris, FranceRecruiting
Service de Neurologie, Réanimation Pédiatriques, Hôpital Raymond Poincaré, Hôpitaux Universitaires, Paris-Ile-de-France-OuestGarches, Île-de-France Region, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05394506